U.S. Pharma Stock News

If you have ever wondered whether Berkshire Hathaway’s share price really reflects what you are getting, you are not alone. This article is designed to help you size up that value for yourself. With the Class A shares last closing at US$745,200, investors have seen a 3.5% return over the past week, a 2.3% decline over the last 30 days, and flat returns year to date and over 1 year, while the 3 and 5 year returns sit at 62.7% and 92.9%. Recent headlines have continued to focus on Berkshire...

Ventas (VTR) continues to attract attention from income focused investors, with its S&P 500 real estate investment trust profile and exposure to senior housing and healthcare facilities across North America and the United Kingdom. See our latest analysis for Ventas. At a share price of $86.21, Ventas has posted an 11.48% year to date share price return, alongside a 31.29% total shareholder return over one year and a 112.30% total shareholder return over three years, which indicates momentum...

Event context and recent share performance Enterprise Financial Services (EFSC) has drawn investor attention after recent trading, with the stock down about 1% over the past day, 6% over the past week, and roughly 10% over the past month. Those shorter term moves contrast with a small positive total return over the past year, as well as higher three and five year total returns. This has prompted some investors to reassess how the bank’s current pricing lines up with its fundamentals. See our...

Why the PX Q650 launch matters for Energy Recovery (ERII) investors Energy Recovery (ERII) has drawn fresh attention after launching its PX Q650 Pressure Exchanger for desalination, combining higher flow capacity, very high stated efficiency, and extended warranties aimed at long-life plant operations. See our latest analysis for Energy Recovery. The PX Q650 launch comes on the heels of Energy Recovery’s recent earnings update. It arrives at a time when the stock has seen a 4.81% 1 day share...

In February 2026, Gilead Sciences presented Phase 3 ARTISTRY-1 and ARTISTRY-2 data showing its investigational single-tablet bictegravir/lenacapavir HIV regimen maintained virologic suppression and was generally well tolerated, proving noninferior to both complex multi-tablet regimens and guideline-recommended single-tablet therapy through Week 48. This potential new once-daily option could simplify treatment for people living with HIV who are currently on complex regimens, reinforcing...

IES Holdings recently held its 2026 Annual Stockholders Meeting, where all director nominees were elected and Ernst & Young was ratified as auditor, while Director Todd Cleveland sold 2,500 shares, trimming his personal stake. Together with ongoing attention on the Gulf Island acquisition, these governance developments are sharpening investor focus on how IES allocates capital and manages oversight. Next, we’ll examine how the director’s share sale and refreshed governance framework shape...

Zevra Therapeutics, Inc. has reported its 2025 results, with full-year sales rising to US$106.47 million and net income reaching US$83.23 million, alongside fourth-quarter revenue of US$34.1 million and adjusted earnings of US$1.16 per share. Alongside these results, Zevra filed a US$22.86 million employee stock offering and named veteran finance executive Justin Renz as its new Chief Financial Officer, underscoring a focus on commercial scale-up and corporate development. We’ll now examine...

Cencora recently reported fiscal first-quarter 2026 adjusted earnings per share of US$4.08, slightly above estimates and 9.4% higher year over year, and raised its full-year guidance for revenue and adjusted operating income while declaring a US$0.60 quarterly dividend. Shareholders reinforced board continuity and executive direction at the 2026 Annual Meeting, as Cencora continues expanding in specialty distribution and European markets while addressing higher expenses and an impairment in...

Resideo Technologies reported past fourth-quarter 2025 results with sales of US$1,895 million and net income of US$136 million, alongside full-year 2025 sales of US$7.47 billion but a net loss of US$527 million. The company also issued 2026 guidance calling for net revenue of US$1,866 million to US$1,890 million in the first quarter and US$7.80 billion to US$7.90 billion for the full year, highlighting a contrast between recent quarterly profitability and a loss-making full year. Against...

RB Global, Inc. recently announced that its Board of Directors has authorized a share repurchase program of up to US$500,000,000, subject to Toronto Stock Exchange approval and funded through cash reserves or its senior credit facility. This sizable buyback authorization, coming alongside strong quarterly results that exceeded analyst expectations, highlights management’s confidence in deploying capital to support shareholder value. We’ll now examine how the newly authorized US$500,000,000...

Cathay General Bancorp (CATY) has drawn investor attention after a recent share price decline, including a 12% drop over the past month, even as the bank reports US$745.261m in revenue and US$315.124m in net income. See our latest analysis for Cathay General Bancorp. That recent 12% monthly share price pullback fits into a softer short term trend, with a 30 day share price return of an 11.79% decline and a 90 day return of a 3.15% decline, even though the 1 year total shareholder return of...

If you are trying to figure out whether Neogen's current share price makes sense, you are not alone. A closer look at its valuation tools can help you frame that question more clearly. Neogen recently closed at US$9.70, with returns of a 13% decline over 7 days, a 10.2% decline over 30 days, a 38.6% gain year to date, and a 2.8% decline over the last year. This combination gives a mixed picture of how the market is currently pricing the stock. Recent coverage around Neogen has focused on the...

Preformed Line Products Company previously reported fourth-quarter 2025 results, with sales rising to US$173.11 million while net income eased to US$8.44 million, and full-year 2025 sales increasing to US$669.34 million alongside slightly lower earnings per share. The combination of higher revenue with reduced profitability suggests rising costs or margin pressure, raising questions about the quality and sustainability of recent growth. We’ll now examine how rising full-year sales alongside...

In February 2026, UMH Properties, Inc. reported past fourth-quarter 2025 sales of US$58.2 million and revenue of US$67.0 million, with full-year 2025 sales of US$226.7 million, revenue of US$261.8 million, and net income of US$26.5 million, all higher than the prior year. While quarterly net income dipped slightly year over year, the improvement in full-year earnings per share from US$0.03 to US$0.07, alongside positive 2026 guidance, highlights UMH’s recent profitability progress. Now we’ll...

In recent weeks, Intellia Therapeutics reported long-term Phase 1/2 data for its CRISPR-based HAE candidate lonvoguran ziclumeran and regained FDA clearance to resume Phase 3 testing of its ATTR-CM therapy nexiguran ziclumeran after agreeing to enhanced liver safety monitoring. Together, these updates highlight Intellia’s push to position one-time in vivo gene-editing treatments as alternatives to chronic therapies in serious genetic diseases. Building on the FDA’s removal of the clinical...

In February 2026, Allot Ltd. reported fourth-quarter 2025 sales of US$28.39 million and net income of US$2.9 million, alongside full-year 2025 sales of US$101.99 million and net income of US$3.71 million, marking a shift from a loss a year earlier. At the same time, the company guided for 2026 revenue of US$113 million to US$117 million, signaling management’s confidence in accelerating growth after its return to profitability. Next, we’ll examine how Allot’s return to profitability and...

Liberty Media Corporation recently announced that Renee Wilm will move from her role as Chief Legal Officer and Chief Administrative Officer of Liberty Media, Liberty Live and Liberty Broadband to become Senior Advisor later in 2026, while continuing as Chief Legal Officer at GCI Liberty, Inc. This shift marks a change in legal and transactional leadership after more than two decades of Ms. Wilm’s involvement in major deals and restructurings across the Liberty group. Next, we’ll assess how...

Why Kyivstar Group is on investors’ radar today Kyivstar Group (KYIV) has caught investor attention after recent trading left the shares around $11.77, with performance over the past month and past 3 months both in negative territory. See our latest analysis for Kyivstar Group. Recent trading has been weak, with a 1-day share price return showing a 0.93% decline and a 90-day share price return showing a 17.58% decline. However, the 1-year total shareholder return of 1.99% indicates that...

Inseego recently introduced the MiFi PRO M4 enterprise mobile router, built on its new ConnectOS software and Qualcomm’s Dragonwing MBB Gen 3 platform, while also unveiling an enhanced Inseego Subscribe SaaS BSS solution for complex enterprise and government subscriber lifecycle management. Together, these launches highlight Inseego’s push to create a unified wireless edge architecture that blends 5G hardware, cloud management, and enterprise-grade security into an integrated offering for...

LeMaitre Vascular, Inc. recently reported fourth-quarter 2025 sales of US$64.45 million and net income of US$15.58 million, alongside full-year 2025 sales of US$249.6 million and net income of US$57.73 million, and announced a higher quarterly dividend of US$0.25 per share plus a share repurchase program of up to US$100 million through February 18, 2027. In addition, the company issued 2026 guidance that points to higher sales and earnings and plans to highlight its outlook at the Leerink...

Why Yalla Group (YALA) is back on investors’ radar Yalla Group (YALA) has drawn fresh attention after its board approved a new share repurchase program of up to US$150 million, alongside first quarter 2026 revenue guidance that factors in the timing of Ramadan. See our latest analysis for Yalla Group. Those moves come after a period where the 1 year total shareholder return of 76.9% contrasts with a more muted 0.7% year to date share price return at US$7.11, suggesting recent momentum has...

In Q2 2025, Mettler-Toledo International reported marginal revenue growth but weaker gross and operating margins as higher tariffs and macroeconomic pressures weighed on profitability, and management issued cautious full-year 2025 guidance. Even as near-term earnings face pressure, the company is emphasizing bioprocessing and manufacturing onshoring as areas it believes could reshape its longer-term business mix. We’ll now examine how the tariff-driven margin squeeze highlighted in the...

Exact Sciences, Amalgam Rx and Privia Health report materially higher colorectal cancer screening rates using EHR-enabled outreach and at home noninvasive tests. The coordinated program is described as scalable and has surpassed national screening benchmarks during Colorectal Cancer Awareness Month. The initiative focuses on closing screening gaps by embedding screening prompts and workflows directly into clinical systems and patient communications. For investors watching NasdaqCM:EXAS,...

Why Nurix Therapeutics (NRIX) moved after its latest capital move Nurix Therapeutics (NRIX) recently expanded its equity distribution agreement, giving it room to sell up to $413.65 million of common stock through Piper Sandler. This step directly affects its capital-raising flexibility and potential dilution. See our latest analysis for Nurix Therapeutics. The capital plan arrives after a tougher few months for the share price, with a 30 day share price return showing an 8% decline and a 90...